Recent Announcements

Guidance Sections Updated

The When and In Whom to Initiate Therapy, Initial Treatment, Retreatment, Acute HCV Infection, and Unique Populations (HIV/HCV Coinfection, Decompensated Cirrhosis, and Renal Impairment) sections have been updated to reflect newly available data presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2015.

Read More

HCV Guidance App

A free HCV Guidance App, a digital version of the HCV Guidance, for your mobile device is available for download. For more information, please click here.

Read More

New Panel Member

We are pleased to announce a new member to the HCV Guidance Panel! Tracy Swan is the Hepatitis/HIV Project Director for Treatment Action Group, and joins the Panel as a Community Representative.

Read More

New Panel Member

We are pleased to announce a new member to the HCV Guidance Panel! Andrew Reynolds is the Hepatitis C Education Manager of Project Inform, and joins the Panel as a Community Representative.

Read More

ION-4 Study Correction in Coinfection

A correction has been made to a typographical error in the description of the ION-4 study, in the ‘Unique Populations: Patients with HIV/HCV Section’ with regard to not recommending a shortened ledipasvir/sofosbuvir treatment course for HIV/HCV coinfected individuals.

Read More

DDI with Amiodarone

A recent FDA alert warns against combining amiodarone with ledipasvir/sofosbuvir or with sofosbuvir taken in combination with another direct acting antiviral. This interaction has been added to the ‘Drug Interaction With Direct-Acting Antivirals and Selected Concomitant Medications’ table in the Initial Treatment section.

Read More

Coinfection Section Updated

The Coinfection section of the HCV Guidance has been updated to incorporate new data from the 2015 Conference on Retroviruses and Opportunistic Infections held from February 23-26, 2015.  Abstracts and webcasts from the conference can be accessed from the IAS-USA website.

Read More

Official Press Release – Developing Section on Cost-Effectiveness of Treatment

The following statement has been released with regard to the Cost-Effectiveness of Treatment section currently in development:
 
Hepatitis C Guidance Website to Develop Section on Cost-Effectiveness of Treatment
 
Read More

Community Representative Nominations for the HCV Guidance Panel Needed

The AASLD and IDSA in collaboration with IAS–USA HCV Guidance Panel is seeking an additional community representative to serve on the panel that drafts the Recommendations for Testing, Managing, and Treating Hepatitis C. Community representatives serve a 2 to 3 year term, similar to the scientific panel members, and are expected to serve on at least one subcommittee and to participate actively in all subcommittee and full committee teleconferences. In-person meetings are not expected to occur more than once annually.

Read More
Top